The University of Liverpool is to co-ordinate a new £14-million European research project that hopes to shed new light on adverse drug reactions through ‘cutting-edge’ modelling approaches to drug safety.
The five-year project, called Translational Quantitative Systems Toxicology to Improve the Understanding of the Safety of Medicines (TransQST), aims to develop novel approaches using the best available data from public and private domains to address drug safety issues.
Adverse drug reactions can contribute significantly to patient morbidity, mortality and hospitalisation costs.
“The fear of ADRs is a major impediment to the development of new, safe and effective therapies,” noted project co-ordinator professor Kevin Park from the University’s Institute of Translational Medicine.
“This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development”.
The project is funded by IMI2, Europe’s largest public-private initiative striving to accelerate development of better and safer medicines for patients.
AstraZeneca, GlaxoSmithKline and Janssen are among the pharma companies involved in TransQST.
